Pharm/Biotech
Resources

Outsourcing Guide

Cont. Education

Software/Reports

Training Courses

Web Seminars

Jobs

Buyer's Guide

Home Page

Pharm Patents /
Licensing

Pharm News

Federal Register

Pharm Stocks

FDA Links

FDA Warning Letters

FDA Doc/cGMP

Pharm/Biotech Events

Consultants

Advertiser Info

Newsletter Subscription

Web Links

Suggestions

Site Map
 

 

 

 

Link:  Pharm/Biotech Resources


Title:  Skin and mucosal treatment formulation

United States Patent:  6,949,262

Issued:  September 27, 2005

Inventors:  Smothers; Don L. (Dallas, TX)

Assignee:  LouSal Enterprises, Inc. (Aledo, TX)

Appl. No.:  445794

Filed:  May 27, 2003

Abstract

A treatment composition for use in providing relief of dryness of the nasal tissues and other dry skin, and particularly to providing such relief without the use of petroleum products.

SUMMARY OF THE INVENTION

The present invention is directed to providing relief of dryness of the nasal tissues and other dry skin, and particularly to providing such relief over an extended period of time and without the use of petroleum products.

More particularly, the present invention is directed to a skin and mucosal treatment composition that is applied to mucosa (such as nasal tissue) or to the skin (such as facial areas exposed to an oxygen mask) and remains in place for a substantial period of time, and which can release moisture to the nasal tissues or treated skin and also forms a barrier on the exposed area to protect it from the drying and chafing activity caused by dry climates, continuous oxygen flow, or oxygen-delivery equipment. By doing so, the user is more comfortable and the nasal tissues and other exposed skin are healthier, without reliance on petroleum products.

The present invention provides a skin and mucosal composition comprising: aloe, dimethicone, allantoin, and water in a carrier base such as an oil, a cream, or a gel.

DETAILED DESCRIPTION OF THE INVENTION

As used herein and in the accompanying claims, the terms "a" and "an" mean "one or more", unless otherwise indicated.

The components of the petroleum-free skin and mucosal treatment composition of the present invention are chosen to be safe for use on the nasal tissues and to be non-irritating.

Useful formulations of the skin and mucosal composition comprise aloe in an amount ranging from about 35 wt % to about 80 wt %, dimethicone in an amount ranging from about 1 wt % to about 3 wt %, allantoin in an amount ranging from about 0.5 wt % to about 3 wt %, and water in an amount ranging from about 20 wt % to about 40 wt %. One presently preferred formulation of the invention comprises about 50 wt % aloe vera, about 2 wt % dimethicone, about 0.6 wt % allantoin, about 35 wt % water, and about 12.4 wt % other ingredients.

Other ingredients or components may be included in the skin and mucosal composition of the invention. Such other components may be selected from, but are not limited to: humectants, preservatives, emollients, buffers, coloring agents, fragrances, solubilizing agents, stabilizing agents, gel-forming agents, oils, antibiotics, herbal materials, and vitamins. Each of these ingredients can be present in any amount that does not substantially interfere with the skin-protecting and skin-moisturizing functions of the treatment composition.

The hydrating skin and mucosal compositions of the present invention are effective at a viscosity preferably ranging from between about 5,000 centipoise to about

300,000 centipoise at room temperature (RT), or about 25° C. Preferably, the viscosity of the composition of the invention is between about 20,000 and about 100,000 centipoise at RT, and more preferably between about 25,000 and 60,000 centipoise.

To treat dry skin or mucosa, the skin and mucosal treatment composition of the invention is administered to the area(s) of the skin or mucosa that exhibit discomfort, soreness, cracking, bleeding, chafing, irritation, or other symptoms of dryness. The treatment composition is applied in an amount and at time intervals as necessary to provide relief from such symptoms. For example, for oxygen users, the composition can be applied at any time during oxygen therapy in sufficient amounts to both the internal and external membranes of the nasal passage, as well as over the ear to reduce friction created by cannula rubbing. CPAP users can apply the treatment composition to the facial area where the oxygen mask meets and covers the skin before beginning therapy. The treatment composition of the invention will not leave a sticky residue on the skin.

The following example further illustrates the invention. However, the invention is not limited thereto, and it will be apparent to those of ordinary skill in the art from the teachings herein that equivalent modifications thereof may be made without departing from the spirit and scope of this invention.

EXAMPLE 1

A skin and mucosal composition was prepared according to the formula shown in Table I.

TABLE I
Ingredient Weight %
Aloe Vera 50.000
Water 34.886
Glycerine 99.5% USP 4.000
Rice Bran Oil 2.000
Emu Oil 2.000
Dimethicone 2.000
DEA oleth-3 phosphate1 2.000
Carbopol 940 1.000
Triethanolamine 99% 0.600
Allantoin 0.600
Undebenzophene-C 0.500
Sodium hydroxymethylglycinate2 0.200
Tocopherol Acetate 0.100
d-L Panthenol 0.100
Fragrance - Baby Powder 0.010
Vitamin A Acetate 0.004
1Crodofos ® N3 Neutral, Croda, Parsippany, NJ
2Suttocide-A ®, Van Wagoner and Associates, Highland Village, TX


PHASE-1

The water and glycerin were mixed together, after which Carbopol was added and dispersed into the mixture with high shear until completely smooth with no lumps. The mixture was then heated to 65° C.

PHASE-2

The emu oil, undebenzophene, DEA oleth-3 phosphate, vitamin A acetate, dimethicone and rice bran oil were mixed together and heated to 65° C.

PHASE-3

The aloe vera, Suttocide A, allantoin, panthenol and tocopherol acetate were added together and agitated until completely dissolved.

When the heated phases reached the specified temperatures, PHASE 2 was added to PHASE 1 until the emulsion was smooth and free of lumps. PHASE 3 was then added to the emulsion with high shear until homogeneous. Cooling of the resulting mixture was begun, with continued regular agitation, and triethanolamine was added. When the batch reaches 30° C., the fragrance was added, with continued agitation, and the pH was adjusted to 5.6±0.3. The final product had the following specifications:

Color white to off-white
Odor light fragrance
Appearance soft cream
Viscosity 32,000-52,000 cps
Specific Gravity 0.995-1.005  
Microbiological Profile:
Total Count 10 cfu/mL max.
Pathogenic Bacteria none
Mold or yeast none


Claim 1 of 11 Claims

1. A skin and mucosal treatment composition comprising of the total amount of the composition:

Aloe vera in an amount ranging from about 35 weight % to about 80 weight %,

dimethicone in an amount ranging from about 1.5 weight % to about 3 weight %,

allantoin in an amount ranging from about 0.5 weight % to about 3 weight %, and

water in an amount ranging from about 20 weight % to about 40 weight %.

____________________________________________
If you want to learn more about this patent, please go directly to the U.S. Patent and Trademark Office Web site to access the full patent.

 

 

[ Outsourcing Guide ] [ Cont. Education ] [ Software/Reports ] [ Training Courses ]
[ Web Seminars ] [ Jobs ] [ Consultants ] [ Buyer's Guide ] [ Advertiser Info ]

[ Home ] [ Pharm Patents / Licensing ] [ Pharm News ] [ Federal Register ]
[ Pharm Stocks ] [ FDA Links ] [ FDA Warning Letters ] [ FDA Doc/cGMP ]
[ Pharm/Biotech Events ] [ Newsletter Subscription ] [ Web Links ] [ Suggestions ]
[ Site Map ]